Table 1. Patient Demographics.

Demographic data for women in the sporadic disease or BRCA-associated cohorts. No significant difference was seen when comparing the age, stage or tumor grade in the two groups. Women with BRCA mutations underwent a greater number of chemotherapy regimens prior to starting Doxil (p=0.004)

	Sporadic Disease Number (%)	BRCA-associated Number (%)	p-value
Age <55	19 (46.3)	13 (56.5)	0.434
≥ 55	22 (53.6)	10(43.5)
Stage I–II	4 (10)	3 (14.3)	0.683
III–IV	36 (90)	18 (85.7)
Grade 1–2	4 (14.3)	1 (5.3)	0.635
Grade 3*	24 (85.7)	18 (94.7)
Mean prior chemotherapy regimens	2.34	3.39	0.004

^*Two patients were unstaged and grade was unknown for 17 cases